On today's episode we discuss novel injectable weight loss drugs (GLP-1 agonists) such as Ozempic and Mounjaro. To discuss these drugs, we are in conversation with Dr. Michael Camilleri, a gastroenterologist from the Mayo Clinic who is specifically interested in how the gastrointestinal motility, obesity, diabetes, appetite, irritable bowel syndrome and related topics. He himself has overseen patients on these drugs and participated in research investigating these medications. Today we discuss which of these medications Dr. Camilleri thinks are likely to become dominant, how these drugs work, their known side effects and safety profiles, in what situations these drugs are likely to be prescribed, what kind of results you can expect, unexpected benefits and drawbacks and how they may be affecting the brain. Interviewed by Dr. Alex Curmi - Give feedback here - [email protected] Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcastIf you would like to enquire about an online psychotherapy appointment with Dr. Alex, you can email - [email protected] Our Mailing List! - https://thinkingmindpod.aidaform.com/mailinglistsignupSUPPORT: buymeacoffee.com/thinkingmindGive feedback here - [email protected] Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.